Dr Richard K Gessner

Richard Gessner is a Senior Investigator at the H3D Drug Discovery and Development Centre at the University of Cape Town (UCT), South Africa. Since taking up the position at H3D in 2014, Richard has been responsible for overseeing tuberculosis (TB) and malaria drug discovery projects that involve multidisciplinary teams (chemistry/biology/ADME/PK) at H3D, with external partners and collaborators (including IDRI, Lilly, GSK, DDU, TAMU, WCMC, Evotec and NIAID) within the TB Drug Accelerator (TBDA – a Bill & Melinda Gates Foundation initiative) and Celgene Global Health (acquired by Bristol-Myers Squibb in 2019). In 2021, Richard took on the additional responsibility of developing H3D’s anti-viral portfolio which initiated from a BRICS collaboration SARS-CoV-2 AI drug discovery programme. Furthermore, he has also played a major role in implementing research project management across H3D after a sabbatical at the Novartis Institute for Biomedical Research (NIBR) in Cambridge, MA, USA, in 2016.

Rua José Dias Pereira, 360
| Jardim Embaixador
Campos do Jordão – SP
CEP: 12460-000 

  • reserva@camposdojordaoeventos.com.br
  • bete@camposdojordaoeventos.com.br
  • (11)9 9750 8361
Facebook Twitter Youtube

Come have a lunch with us and meet two ACS editors in another edition of ACS on Campus: Lori Ferrins – Topic Editor, Journal of Medicinal Chemistry; and Carolina Horta – Associate Editor, ACS Omega. The event will be part of 11th BrazMedChem and 9th BCNP programs. We will discuss valuable tips on how to prepare your manuscript in an efffective way as well as what our editors expect about an impactful paper. In addition, we will talk about Open Access and its impact on the visibility and democratization of scientific knowledge. The ACS on Campus will be held on Oct 25 at 12 PM (local time). All attendees will recieve a lunch box and a certificate. Register here: cvent.me/4K1qLP #ACSonCampus